Drug Type Small molecule drug |
Synonyms 2-Dimethylamino-2-phenylbutyl 3,4,5-trimethoxybenzoat, Modulon SR, Trimebutine + [12] |
Action agonists, antagonists |
Mechanism Opioid receptors agonists(Opioid receptors agonists), mAChRs antagonists(Muscarinic acetylcholine receptor antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization- |
Active Organization |
Inactive Organization |
License Organization- |
Drug Highest PhaseApproved |
First Approval Date Japan (15 Feb 1984), |
Regulation- |
Molecular FormulaC26H33NO9 |
InChIKeyFSRLGULMGJGKGI-BTJKTKAUSA-N |
CAS Registry34140-59-5 |
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| D01500 | Trimebutine Maleate |
| Indication | Country/Location | Organization | Date |
|---|---|---|---|
| Gastrointestinal Diseases | China | 01 Jan 2000 | |
| Irritable Bowel Syndrome | Japan | 31 May 1988 | |
| Chronic gastritis | Japan | 15 Feb 1984 |
Phase 2 | Hormone receptor positive HER2 negative breast cancer estrogen receptor-positive | HER2-negative | - | Bifidobacterial | slwgquxbof(mbdenjhway) = ipehsfxjpd ctacurjqjk (aggwcmcwnj ) View more | - | 16 Sep 2021 | |
Bifidobacterial and Trimebutine Maleate | slwgquxbof(mbdenjhway) = fpsswqfsss ctacurjqjk (aggwcmcwnj ) View more |





